| Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer (NCT05356039) | Umeå University | 2022-04-19 |
| PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer (NCT05524090) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2021-07-01 |
| Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (NCT04570943) | Institut du Cancer de Montpellier - Val d'Aurelle | 2021-06-16 |
| FAZA PET/MRI Pancreas (NCT04395469) | University Health Network, Toronto | 2021-05-18 |
| Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer (NCT04718701) | The First Affiliated Hospital with Nanjing Medical University | 2021-04-01 |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (NCT04172532) | National Cancer Institute (NCI) | 2021-01-11 |
| First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer (NCT04665947) | University of California, Davis | 2020-12-18 |
| Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer (NCT04669197) | HonorHealth Research Institute | 2020-12-01 |
| Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. (NCT04652206) | Scandion Oncology A/S | 2020-10-27 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC (NCT03673137) | Fuda Cancer Hospital, Guangzhou | 2019-09-01 |
| Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer (NCT03536182) | University of Texas Southwestern Medical Center | 2019-05-29 |
| Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) (NCT04423731) | Oslo University Hospital | 2018-01-01 |
| Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma (NCT03077685) | NanOlogy, LLC | 2017-12-01 |
| BATs Treatment for Pancreatic Cancer, Phase Ib/II (NCT03269526) | University of Virginia | 2017-07-28 |
| Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer (NCT02394535) | M.D. Anderson Cancer Center | 2015-11-12 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT01585805) | National Cancer Institute (NCI) | 2012-05-15 |
| Immunochemoradiotherapy in Patients With Pancreatic Cancer (NCT01342224) | Providence Health & Services | 2011-01-01 |
| Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (NCT00669734) | National Cancer Institute (NCI) | 2010-02-01 |
| Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection (NCT01278368) | Università Vita-Salute San Raffaele | 2003-01-01 |
| Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA) (NCT07319910) | NovoCure GmbH | |